Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclic glycine-proline
- Development stage
- Unknown
- Lead developer
- cGP Lab
- Modality
- Peptides, Small Molecules
- Administration
- Oral
01
Overview
Cyclic glycine-proline (cGP) is a naturally occurring cyclic dipeptide belonging to the 2,5-diketopiperazine family and is an endogenous metabolite of insulin-like growth factor-1 (IGF-1). Developed by The cGP Lab Ltd. in New Zealand, cGP functions as a regulator of IGF-1 bioavailability by competing for binding sites on insulin-like growth factor-binding protein 3 (IGFBP-3). This mechanism helps normalize IGF-1 function, which is critical for metabolic and neurological health. The compound is being evaluated in clinical trials for metabolic syndrome, insulin resistance, and obesity, and is also under investigation for neuroprotective applications in conditions such as Parkinson's disease, Alzheimer's disease, and age-related cognitive decline. Commercial formulations, such as cGP-PRo®, are derived from New Zealand blackcurrant cultivars and hydrolysed collagen peptides.
- Brand names
- cGP-PRocGPMAX
- Other names
- Cyclo-glycyl-prolineCyclo(Gly-Pro)GPE metabolite
02
Targets
AMPAR (AMPA receptor)GABRR (GABA-A receptor subunit rho)Insulin-like growth factor 1/Insulin-like growth factor-binding protein 3 protein–protein interface
Beyond the preview
Go deeper on cyclic glycine-proline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclic glycine-proline.